Vitality Watch

Dossier pubmed trial late 01-oct-2026
Large or late-phase randomized human trial

Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND.

Key claim: An indirect imputed-placebo analysis estimated that tirzepatide reduced MACE-3 (HR 0.72), CV death or heart-failure events, and all-cause death versus placebo in people with type 2 diabetes and established atherosclerotic CVD.

Abstract

OBJECTIVE: In prespecified analyses, the treatment effect for major adverse cardiovascular event (MACE) of tirzepatide compared with imputed placebo was estimated using SURPASS-Cardiovascular Outcomes Trial (SURPASS-CVOT) and Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) trial data. RESEARCH DESIGN AND METHODS: The indirect comparison with placebo was conducted for primary (MACE-3) and secondary outcomes of SURPASS-CVOT. The analysis included data from REWIND participants who would have been eligible for SURPASS-CVOT and all participants from SURPASS-CVOT. Propensity score estimation was used to adjust for differences in participant characteristics between studies. The indirect analysis of the treatment effect was derived by multiplying the hazard ratio (HR) for MACE-3 between tirzepatide and dulaglutide in SURPASS-CVOT by the HR for dulaglutide versus placebo in REWIND. Sensitivity analyses were performed using unadjusted analyses, including both the selected REWIND and the entire REWIND populations, and adjusted analysis in the entire REWIND population. Post hoc sensitivity analyses used data from a recent glucagon-like peptide 1 receptor agonist (GLP-1RA) meta-analysis that included REWIND. RESULTS: Analyses included 2,055 of 9,901 participants from REWIND and all 13,165 participants from SURPASS-CVOT. In indirect treatment effect comparisons, tirzepatide versus placebo was associated with lower MACE-3 (HR 0.72; 95% CI 0.55, 0.94), death from CV cause or heart failure events (HR 0.70; 95% CI 0.51, 0.96), and all-cause death (HR 0.61; 95% CI 0.45, 0.82). Sensitivity analyses, including nonadjusted or the entire REWIND cohort data or meta-analysis data for GLP-1RAs, were generally consistent. CONCLUSIONS: In this indirect prespecified exploratory comparison, tirzepatide compared with imputed placebo was associated with reduced CV outcomes and all-cause mortality in participants with type 2 diabetes and established atherosclerotic CV disease.

Why this matters

Tirzepatide’s active-comparator SURPASS-CVOT design can’t directly show placebo-relative cardiovascular benefit, so an imputed-placebo analysis anchored to REWIND is how the field is bridging that gap. The estimated MACE and mortality reductions suggest the dual GIP/GLP-1 agonist carries cardioprotection on the same order as pure GLP-1RAs, consolidating incretin-class CV benefit rather than revealing a new mechanism. The caveat is methodological: the ‘placebo’ arm is statistical, not randomized.

Source

Link

Briefing card

Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND.
Stage: trial late · pubmed · 01-oct-2026

If you're on tirzepatide for type 2 diabetes with established cardiovascular disease, this indirect analysis estimates a MACE and mortality reduction similar to older GLP-1 agonists, though it was inferred from a borrowed placebo arm rather than measured directly.

An indirect imputed-placebo analysis estimated that tirzepatide reduced MACE-3 (HR 0.72), CV death or heart-failure events, and all-cause death versus placebo in people with type 2 diabetes and established atherosclerotic CVD.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.2337/dc26-0298

build build 880 · 2bcef25 · 2026-11-18